Breast milk oxycodone concentrations in mothers given oxycodone for post-Caesarean delivery pain management.
Caesarean delivery
breast milk
neonate
oxycodone
pain
postoperative
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
02 Feb 2024
02 Feb 2024
Historique:
revised:
15
12
2023
received:
02
11
2023
accepted:
13
01
2024
medline:
3
2
2024
pubmed:
3
2
2024
entrez:
3
2
2024
Statut:
aheadofprint
Résumé
Both effective analgesia and early breastfeeding play an important role in maternal and neonatal well-being after Caesarean delivery. We studied controlled-release oxycodone tablet treatment for postoperative pain management and determined the excretion of oxycodone into breast milk. Controlled-release oxycodone/naloxone 10/5-mg tablets (n = 21) or controlled-release oxycodone 10-mg tablets (n = 22) were administered to mothers twice a day for the first 3 days after elective Caesarean delivery as a part of multimodal analgesia. Maternal plasma and breast milk samples were collected daily. Oxycodone, noroxycodone, oxymorphone and noroxymorphone concentrations were analysed with ultra-performance liquid chromatography-mass spectrometry. Maternal pain intensity was recorded with an 11-point Numeric Rating Scale (0-10). Neonatal oxycodone exposure was estimated by simulating five different exposure scenarios, including the highest possible exposure through breast milk. The mean oxycodone and noroxycodone milk-to-maternal plasma ratios were 3.2 and 3.0, respectively. A strong correlation was found between plasma and breast milk oxycodone (R The oxycodone dose received from colostrum and breast milk during the first three postoperative days after Caesarean delivery is assumed safe for healthy, term neonates, but in extreme cases it is possible for the neonate to receive a dose through breast milk that may elicit opioid effects.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Suomen Kulttuurirahasto
ID : 00160447
Informations de copyright
© 2024 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Mäkelä K, Palomäki O, Pokkinen S, Yli-Hankala A, Helminen M, Uotila J. Oral versus patient-controlled intravenous administration of oxycodone for pain relief after Cesarean section. Arch Gynecol Obstet. 2019;300(4):903-909. doi:10.1007/s00404-019-05260-3
Lam J, Kelly L, Ciszkowski C, et al. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. J Pediatr. 2012;160(1):33-37. doi:10.1016/j.jpeds.2011.06.050
Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132(3):e796-e809. doi:10.1542/peds.2013-1985
Evans KC, Evans RG, Royal R, et al. Effect of Caesarean section on breast milk transfer to the normal term newborn over the first week of life. Arch Dis Child Fetal Neonatal Ed. 2003;88(5):380-382. doi:10.1136/fn.88.5.F380
Hobbs AJ, Mannion CA, McDonald SW, et al. The impact of Caesarean section on breastfeeding initiation, duration and difficulties in the first four months postpartum. BMC Pregnancy Childbirth. 2016;16(1):90-91. doi:10.1186/s12884-016-0876-1
Eisenach JC, Pan PH, Smiley R, Lavand'homme P, Landau R, Houle TT. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain. 2008;140(1):87-94. doi:10.1016/j.pain.2008.07.011
PubChem. (2023). Oxycodone. Accessed online 3.1.2023. https://pubchem.ncbi.nlm.nih.gov/compound/Oxycodone#section=Stability-Shelf-Life
Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacokinet. 2019;58(6):705-725. doi:10.1007/s40262-018-00731-3
Kokki M, Välitalo P, Rasanen I, et al. Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Eur J Clin Pharmacol. 2012a;68(10):1357-1363. doi:10.1007/s00228-012-1267-9
Pöyhiä R, Seppälä T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992;33(6):617-621. doi:10.1111/j.1365-2125.1992.tb04090.x
Valtola A, Morse JD, Florkiewicz P, et al. Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial. J Drug Assess. 2020;9(1):117-128. doi:10.1080/21556660.2020.1797753
Seaton S, Reeves M, McLean S. Oxycodone as a component of multimodal analgesia for lactating mothers after Caesarean section: relationships between maternal plasma, breast milk and neonatal plasma levels. Aust N Z J Obstet Gynaecol. 2007;47(3):181-185. doi:10.1111/j.1479-828X.2007.00715.x
Kokki M, Heikkinen M, Välitalo P, et al. Maturation of oxycodone pharmacokinetics in neonates and infants: oxycodone and its metabolites in plasma and urine. Br J Clin Pharmacol. 2017a;83(4):791-800. doi:10.1111/bcp.13164
Välitalo P, Kokki M, Ranta VP, Olkkola KT, Hooker AC, Kokki H. Maturation of oxycodone pharmacokinetics in neonates and infants: a population pharmacokinetic model of three clinical trials. Pharm Res. 2017;34(5):1125-1133. doi:10.1007/s11095-017-2122-6
Kokki M, Broms S, Eskelinen M, Rasanen I, Ojanperä I, Kokki H. Analgesic concentrations of oxycodone-a prospective clinical PK/PD study in patients with laparoscopic cholecystectomy. Basic Clin Pharmacol Toxicol. 2012b;110(5):469-475. doi:10.1111/j.1742-7843.2011.00839.x
Verstegen RHJ, Anderson PO, Ito S. Infant drug exposure via breast milk. Br J Clin Pharmacol. 2020;1-17(10):4311-4327. doi:10.1111/bcp.14538
Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461-479. doi:10.1016/j.clpt.2006.01.009
Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi:10.1002/cpt.377
Morse JD, Hannam JA, Anderson BJ, Kokki H, Kokki M. Oxycodone target concentration dosing for acute pain in children. Paediatr Anaesth. 2021;31(12):1325-1331. doi:10.1111/pan.14282
Olkkola KT, Hamunen K, Seppälä T, et al. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol. 1994;38(1):71-76. doi:10.1111/j.1365-2125.1994.tb04324.x
Kokki M, Kuronen M, Naaranlahti T, et al. Opioid-induced bowel dysfunction in patients undergoing spine surgery: comparison of oxycodone and oxycodone-naloxone treatment. Adv Ther. 2017b;34(1):236-251. doi:10.1007/s12325-016-0456-9
Kuusniemi K, Zöllner J, Sjövall S, et al. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice. J Int Med Res. 2012;40(5):1775-1793. doi:10.1177/030006051204000516
Alexander SPH, Christopoulos A, Davenport AP, et al. The concise guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. Br J Pharmacol. 2023;180(52):S23-S144.